<DOC>
	<DOCNO>NCT00931762</DOCNO>
	<brief_summary>This study ass safety efficacy Panobinostat single agent treatment Primary Myelofibrosis , Post-Polycythemia Vera Post-Essential Thrombocythemia . There two cohort - patient JAK2 mutation patient without JAK2 mutation .</brief_summary>
	<brief_title>Safety Efficacy Panobinostat Patients With Primary Myelofibrosis</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>1 . Diagnosis myelofibrosis , either PMF , postPV postET MF IPSS score 2 ( intermediate risk ) 3 ( high risk ) plus least one following : Symptomatic spenomegaly ( ≥10cm BCM ) Hemoglobin &lt; 10 red cell transfusion dependent . ( The presence JAK2 V617F mutation require study entry ) 2 . Patients must meet follow laboratory criterion : Patients either JAK2 V617F mutate wild type Serum potassium , magnesium , phosphorous , sodium , total calcium ( correct serum albumin ) ionize calcium within normal limit ( WNL ) institution Note : Potassium , magnesium , phosphorous , sodium , and/or calcium supplement maybe give correct value &lt; LLN . Post correction value must deem clinically significant abnormality prior patient dose . Creatinine &lt; 1.5 X ULN Calculated CrCl ≥ 50 mL/min ( MDRD Formula ) AST ALT ≤ 2.5 x ULN Serum total bilirubin ≤ 1.5 x ULN 3 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤ 2 4 . Clinically euthyroid . Note : Patients permit receive thyroid hormone supplement treat underlying hypothyroidism . 1 . Prior HDAC , DAC , HSP90 inhibitor valproic acid treatment cancer 2 . Previous treatment JAK2 inhibitor 3 . Any patient previously receive radiation therapy ≥ 30 % bone marrow 4 . Impaired cardiac function clinically significant cardiac diseases 5 . Patient unresolved diarrhea ≥ grade 2 6 . Patients use medication relative risk prolong QT interval induce Torsade de pointes treatment discontinue switched different medication prior start study drug 7 . Patients undergone major surgery ≤ 4 week prior start study drug recover side effect surgery 8 . Women pregnant breast feed woman childbearing potential ( WOCBP ) use effective method birth control . WOCBP define sexually mature woman undergone hysterectomy naturally postmenopausal least 12 consecutive month ( i.e. , menses time precede 12 consecutive month ) . Women childbearing potential must negative serum pregnancy test screen baseline . 9 . Male patient whose sexual partner WOCBP use effective birth control 10 . Patients prior malignancy last 5 year ( except basal squamous cell carcinoma , situ cancer cervix ) 11 . Patients know positivity human immunodeficiency virus ( HIV ) hepatitis C ; baseline test HIV hepatitis C require Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Bone marrow</keyword>
	<keyword>Myelofibrosis</keyword>
	<keyword>JAK2mutation</keyword>
	<keyword>Post-Polycythemia Vera</keyword>
	<keyword>Post-Essential Thrombocytopenia</keyword>
</DOC>